MicroRNAs as master regulators of FOXO transcription factors in cancer management

Rani, Madhu; Kumari, Rashmi; Singh, Shashi P.; Devi, Annu; Bansal, Preeti; Siddiqi, Aisha; Alsahli, Mohammed A.; Almatroodi, Saleh A.; Rahmani, Arshad Husain; Rizvi, M. Moshahid Alam

doi:10.1016/j.lfs.2023.121535

Cited by 5 publications

(2 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TTP responds to dexamethasone in MDA-MB-231 cells and reduces proliferation, and this effect is suppressed by the FOXO1 binding to its promoter, but only in the presence of dexamethasone [136]. In addition, miRNAs that are dysregulated in TNBC also target FOXO pathways [137,138]. In particular, miRNA-155 targets and downregulates the mRNA FOXO3a, among others, in chemo-resistant breast cancer cells [139].…”

Section: Foxomentioning

confidence: 99%

The Involvement of Peroxiporins and Antioxidant Transcription Factors in Breast Cancer Therapy Resistance

Milković,

Mlinarić,

Lučić

et al. 2023

Cancers

View full text Add to dashboard Cite

Breast cancer is still the leading cause of death in women of all ages. The reason for this is therapy resistance, which leads to the progression of the disease and the formation of metastases. Multidrug resistance (MDR) is a multifactorial process that leads to therapy failure. MDR involves multiple processes and many signaling pathways that support each other, making it difficult to overcome once established. Here, we discuss cellular-oxidative-stress-modulating factors focusing on transcription factors NRF2, FOXO family, and peroxiporins, as well as their possible contribution to MDR. This is significant because oxidative stress is a consequence of radiotherapy, chemotherapy, and immunotherapy, and the activation of detoxification pathways could modulate the cellular response to therapy and could support MDR. These proteins are not directly responsible for MDR, but they support the survival of cancer cells under stress conditions.

show abstract

Section: Foxomentioning

confidence: 99%

The Involvement of Peroxiporins and Antioxidant Transcription Factors in Breast Cancer Therapy Resistance

Milković,

Mlinarić,

Lučić

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In numerous cancer types, miRNA-183 has been demonstrated to have both tumor-suppressive and oncolytic functions ( Hussein et al, 2021 ). miRNA-183 targets programmed cell death 4 (PDCD4) and Fork-head box O3 (FOXO3) to increase proliferation and invasion in human carcinoma ( Cao et al, 2020 ; Rani et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of anti-cancer effects of carnosine and melittin-loaded niosomes in MCF-7 and MDA-MB-231 breast cancer cells

Hussein,

Abdelfattah-Hassan,

Eldoumani

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: We investigated the anti-cancer effect of carnosine-loaded niosomes (Car-NIO) and melittin-loaded niosomes (Mel-NIO) with olaparib in breast cancer cell lines (MCF-7 and MDA-MB-231).Methods: The thin film method was used for preparing the niosomes and characterized in terms of morphology, size, and polydispersity index (PDI). We further evaluated the impact of these peptides on breast cancer cells viability, RT-qPCR assays, malondialdehyde (MDA) activity, and cell cycle progression, to determine if these are linked to carnosine and melittin’s anti-proliferative properties.Results: Car-NIO and Mel-NIO in vitro study inhibited cancer cell viability. They have also upregulated the expression of protein 53 (P53), BCL2-Associated X Protein (Bax), caspase-9, caspase-3, programmed cell death 4 (PDCD4), and Forkhead box O3 (FOXO3), while downregulated the expression of B-cell lymphoma 2 (Bcl2), poly (ADP-ribose) polymerase (PARP 1), and MicroRNA-183 (miRNA-183). The MCF-7 cells were arrested at the G2/M phase in Car-NIO, on the other hand, the MDA-MB-231 cells were arrested at the S phase. While the Mel-NIO and olaparib arrested the MCF-7 and MDA-MB-231 cells at the G0/1 phase.Conclusion: Our study successfully declared that Mel-NIO had more anti-cancer effects than Car-NIO in both MCF-7 and MDA-MB-231 breast cancer cells.

show abstract

FOXO1, a tiny protein with intricate interactions: Promising therapeutic candidate in lung cancer

Ebrahimnezhad,

Natami,

Bakhtiari

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

MicroRNAs as master regulators of FOXO transcription factors in cancer management

Cited by 5 publications

References 151 publications

The Involvement of Peroxiporins and Antioxidant Transcription Factors in Breast Cancer Therapy Resistance

The Involvement of Peroxiporins and Antioxidant Transcription Factors in Breast Cancer Therapy Resistance

Evaluation of anti-cancer effects of carnosine and melittin-loaded niosomes in MCF-7 and MDA-MB-231 breast cancer cells

FOXO1, a tiny protein with intricate interactions: Promising therapeutic candidate in lung cancer

Contact Info

Product

Resources

About